Insulin Innovation.

Slides:



Advertisements
Similar presentations
What's New in Basal Insulin for Diabetes
Advertisements

Copyright © 2015 by the American Osteopathic Association.
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
THE EFFICACY GAP BETWEEN CLINICAL TRIAL AND
Short-, Intermediate-, Long-Acting Insulins
Diabetic Dyslipidemia in Practice
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
Special Consideration in Insulin Therapy
Modern Strategies for Basal Insulin Use in T2D
What Comes Second?.
Insulin Innovation.
Insulin/GLP-1 Agonist Combinations
Medication Nonadherence in Gout
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
How Early Should Basal Insulin Be Used in T2D Management?
Updates Abound.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Examining CV Effects of Basal Insulin Therapy
Surveying the Safety of NOACs in the Real World
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Emerging CVOT Data and Clinical Application
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Emerging Basal Insulins for Diabetes
GLP-1 Receptor Agonists: How Early Is Appropriate?
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Breaking Down the CVOTs
Insulin/GLP-1 Agonist Combinations
Insulin Innovation.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
Extending Treatment for Thrombosis: What’s the Right Choice?
The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
Predictive Low Glucose Suspend (PLGS)
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
T2DM Management.
Better Diabetes Control With Novel Basal Insulins
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Dual SGLT1/SGLT2 Inhibition in T1D
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
Application of Biologics in IBD:
Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.
Are All Novel Insulins Proven to Be Equally Safe?
Deep Dive: Examining Emerging GLP-1 RAs From a Clinical Perspective
Emerging Combination Injectable Therapy A New Era in Diabetes Care
ADA/EASD general recommendations for type 2 diabetes management (1).
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Fixed-Ratio Combination Therapy in T2DM
ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
Emerging Basal Insulins for Diabetes
Fresh perspectives ON BASAL Insulins in diabetes care
In the Know.
The Challenge of Insulin Titration
Presentation transcript:

Insulin Innovation

Program Overview

What Does “Real-World” Data Mean?

Clinical Trials Do Not Always Predict Results in Clinical Practice

Efficacy Gap With GLP-1 RA and DPP-4i

The Role of Adherence in the Efficacy Gap

DUNE: Study Objective and Design

DUNE: Results

Titration of Basal Insulin

Basal Insulin: Persistence and Adherence

Basal Insulin: Persistence and Adherence (cont)

DELIVER 1

DELIVER 2

DELIVER 2 (cont)

DELIVER 3

Collecting Data on Hypoglycemia

Real-World Data on Insulin Degludec

EU-Treat

Pragmatic Trials

ACHIEVE

REACH

REGAIN

Summary and Outlook

Summary and Outlook (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.